Drugmaker Wockhardt has approached the Drug Controller General of India (DCGI) seeking approvals for its fast-acting insulin analog, Aspart injection. The company’s Aspart insulin injection ...

The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes mellitus have been reported in several studies. BIAsp 30 has been shown to be more effective in ...

Clin Drug Invest. 2004;24(12):695-717. Finally, subcutaneous insulin aspart every 1 or 2 hours was a well tolerated and cost-effective alternative to a standard intravenous protocol of regular ...

Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ...

Other companies have developed smart insulin pens, notably Medtronic with its InPen device, but Novo Nordisk is the first to make the technology available to NHS patients in the UK. Lilly is ...

Wockhardt has filed for marketing approval of its fast-acting insulin analog, Aspart injection, with the DCGI in India. This move aims to address the growing diabetes epidemic and provide patients ...

The sharp movement in the early deals was seen after the company announced that it had filed its fast-acting insulin analog, Aspart injection (ASPARAPID), with the Drug Controller General of India.

Recent Market Developments: In Nov 2020, the launch of the InPen coupled with real-time1 Guardian Connect CGM data was announced by Medtronic plc. In April 2020, Dupixent, a novel prefilled pen from ...